Neuromuscular pathology in ALS involves the systemic regulation of inflammatory markers mostly active on T-cell immune responses. Disease stratification based on the prognostic value of circulating inflammatory markers could improve clinical trials design in ALS.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: